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ATTEMPTS to use radioactive fluorene disulphonamides in the diagnosis of
internal cancer failed to prove their highly specific affinity to tumour tissue which
could localize and determine a neoplasm at its early stage of development. It
was found, however, that some fluorene disulphonamido derivatives might be
used to determine an affected phagocytic function of the reticulo-endothelial
system in the presence of tumour (Argus, Hewson and Ray, 1956; Argus, 1961;
Malejka, Argus and Ray, 1963; Argus, Hudson, Seepe, Kane and Ray, 1962;
Malejka, 1962). N,N'-bis(naphthalene)-2,7-fluorene[35S]disulphonamide was the
subject of particularly extensive studies; its diagnostic value was examined in
mice bearing a transplanted squamous cell stomach carcinoma (Argus and Hewson,
1954), in Syrian hamsters with sarcoma and in rats bearing Walker carcinosarcoma
256 (Argus, Hudson, Seepe, Kane and Ray, 1962). In all cases, the concentration
ratio of the disulphonamide in the liver and spleen of control animals and in the
same organs of tumour-bearers exceeded 1. This revealed an impaired function
of the liver and spleen in the presence of tumour. Examining N,N'-bis(sulpha-
moyl-phenyl)-2,7-fluorene[35S]disulphonamide it was found that the spleen of
tumour-free rats localized 4 times more of this compound than the spleen of
tumour-bearers (Malejka, 1962). Comparison of the results for the naphthalene
derivative in the animals bearing various tumours to its behaviour under stress
conditions showed an opposite effect, consisting in a decreased uptake of the
disulphonamide by the liver and spleen of control animals (Argus, Kane and Ray,
1960; Malejka, Argus and Ray, 1961).
In the present investigation two known sulphonamido substituents: amino-
thiazole and guanidine were chosen for obtaining N,N'-bis(thiazole)-2,7-fluo-
rene[35S]disulphonamide, I, and N,N'-bis(guanidine)-2,7-fluorene[35S]disulphon-
amide, II, respectively.
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These compounds were examined in Wistar rats bearing transplanted Walker
carcinosarcoma and in control animals, in an attempt to find a favourable tumour
localization and to compare the reaction of the reticulo-endothelial system to
these new compounds with the reaction to the fluorene derivatives previously
investigated.
MATERIALS AND METHODS
2,7-Fluorene[35S]disulphonylchloride.-The procedure described previously
(Argus and Hewson, 1954) was employed, but 50 millicuries of 35S were used
with the same quantities of other reactants. The yield of crude material was
25 g. (71 per cent of theory). Recrystallization from toluene gave 6 g. of the
product (17 per cent of theory), melting at 220-221°; specific activity was not
determined on this intermediate.
N,N'-bis(thiazole)-2,7-fiuorene[35S]disulphonamide, I.-2-Amino-thiazole, 4-1 g.
(0.041 moles) was dissolved in 25 ml. acetone at 55-60° (water bath). The solution
was stirred and maintained at the same temperature throughout the addition
(15 minutes) of solid 2,7-fluorene[35S]disulphonylchloride, 3 g. (0.008 moles) and
through the following 4 hours. The brown reaction mass which settled on the
flask walls was separated from the acetone solution, and hot distilled water was
then added to the brown residue. The resulting yellow precipitate was collected,
washed free of 2-amino-thiazole hydrochloride with hot distilled water, and dried
over phosphorus pentoxide. The yield of crude material was 3 g. (75 per cent of
theory) melting at 280°. Purification from pyridine with charcoal and precipita-
tion with methanol gave 1 g. (25 per cent of theory) of a cream-coloured product
melting at 306-308' (315° decomposition) and having a specific activity of 4800
disintegrations per second per mg. (0.13 ,ac per mg.).
Analysis. Calculated for Ci9H14N4S404 (molecular weight 490.6): C, 46-51
H, 2.87 ; N, 11.42; S, 26-14. Found: C, 46-21 ; H, 3 07 ; N, 11-46; S, 26-01.
N,N'-bis(guanidine)-2,7-fiuorene[35S]disulphonamide, II.-Guanidine hydro-
chloride, 1-3 g. (0.013 moles) was dissolved in 2 ml. water and 7 ml. acetone at
55-60° (water bath). The solution was stirred and maintained at the same
temperature throughout the addition (15 minutes) of solid 2,7-fluorene[35S]-
disulphonylchloride, 1 g. (0.0027 moles), and through the foliowing 5 hours. The
white precipitate was allowed to cool to room temperature and was then collected,
washed with methanol, and dried over phosphorus pentoxide. The yield of
crude material was 1 g. (81.7 per cent of theory), melting point 273°. Recrystal-
lization from 80 per cent ethanol gave 0-8 g. (65.4 per cent of theory) of a white
product melting at 324° and having a specific activity of 4200 disintegrations per
second per mg. (0.11 wc per mg.).
Analysis. Calculated forC15H16N6S204.2H20 (molecular weight 444.5) : C,40-53;
H, 4.53 ; N, 18-91 ; S, 14.42. Found: C, 40-49; H, 4.29; N, 18-97.
Animal experiments. A total of 22 young male Wistar rats was used; 10
were employed for subcutaneous transplantation ofWalker carcinosarcoma (which
was received from the Department of Pathological Anatomy, Medical Academy,
Gdansk); 12 tumour-free rats served for the control groups. When the tumours
were 12-20 days old and averaged 15 g. in weight, the radioactive compounds
were administered by tail vein injection. Each rat was given 1.2 ml. 0.05 N NaOH
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containing 12 mg. N,N'-bis(thiazole)-2,7-fluorene[35S]disulphonamide, I, or
N,N'-bis(guanidine)-2,7-fluorene[35S]disulphonamide, II, and then placed in an
individual metabolism cage and killed 6 hours following administration of the
compounds. The concentration and per cent recovery of radioactive material
in tissues and excreta of rats were determined by methods described previously
(Argus, Kane and Ray, 1960). In the present experiment brain was taken
separately and 10 ml. of 0-25 N NaOH was added per g. of tissue. Radioactivity
measurements were made in a gas-flow GM counter of low background with
automatic sample changerfrom " Tracerlab ". Aproportionalgasandwindowless
counter was used. Its efficiency was 74.7 per cent.
RESULTS AND DISCUSSION
The complete tissue distribution of N,N'-bis(thiazole)-2,7-fluorene[35S]-
disulphonamide, I, and N,N'-bis(guanidine)2,7-fluorene[35S]disulphonamide, II,
between Wistar rats bearing a transplanted Walker carcinosarcoma and tumour-
free animals was compared. In order to obtain data which could be compared to
those for the compounds tested previously (Argus, Kane and Ray, 1960; Malejka,
Argus and Ray, 1961; Malejka, 1962), this investigation was also conducted with
a 6 hours' time interval between administration and killing. The details ofthese
studies for compounds I and II are shown in Table I. Both concentrations,
TABLE I.-Distribution of Radioactivity in Tumour-bearing and Tumour-free
Wistar Rats after Intravenous Injection of N,N'-bis(thiazole)-2,7-Fluorene[35S]-
disulphonamide, I, andN,N'-bis(guanidine)-2,7-Fluorene[35S]disulphonamide, II*
Tissue
Blood cells§
Blood plasma§
Brain
Liver
Lungs
Spleen
Kidneys
Skin
Leg muscle.
Stomach + contents
Small intestine + contents
Large intestine + contents
Carcass
Urine§
Faeces
Tumour
Total
Compound I
Experimental Control
groupt groupl
Per Per
c4g./g. cent /ug./g. cent
22 0 94 6 0-28
80 3-15 114 5-85
0 0 00 5 0-02
596 32-08 520 31-08
69 0-38 34 0 46
120 0 65 59 0 36
101 1-05 62 0 76
149 33-02 98 3089
12 0-17 10 0 26
19 0 25 14 0-17
184 6*59 76 3.58
11 0-25 161 8-03
4 1*62 6 1-76
276tt 2-61 619 5.39
-- 45t 0 03
35 8-03 -
90 79 - 88-92
Compound II
Experimental Control
group$ group$
Per Per
,ug./g. cent pug./g. cent
0 0.00 0 0.00
18 2 00 9 0 50
0 0.00 0 0 00
7** 0 34 0 0 00
8 0-06 5 0 03
7t 0 04 0 0.00
40 0 45 15 0-18
21 5-54 44 14-22
0 0.00 0 0 00
58 0-60 5 0-01
210 870 35** 1-47
254 7-62 121 5-45
5** 0 70 0 0.00
8146 73-17 9640 80 36
288tt 1*06 100tt 0-31
0 0 00
- 100 28 - 102 53
* Dose of 35S-labelled compound I or II-12 mg. per rat.
t Average value from 4 rats.
$ Average value from 6 rats.
§ Concentration in ,ug. compound/ml.; other data are inpsg. compound/g. tissue.
** Average value from 5 rats.
tt Average value from 3 rats.
t Average value from 2 rats.
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expressed in ,ag. of compound per g. tissue or ml. blood or urine, and in percentages
of administered dose recovered are given. Differences between the distribution of
the two fluorene derivatives are markedly apparent. While N,N'-bis(thiazole)-
2,7-fluorene[35S]isulphonamide, I, was taken up by various organs and tissues
and retained in the animal organism, N,N'-bis (guanidine)-2,7-fluorene[35S]-
disulphonamide, II, was almost completely excreted (73-80 per cent of the dose
6 hours following administration) in the urine. The small amounts of II deter-
mined in other organs and tissues were not further considered. This different
behaviour of two 35S-labelled compounds in rats may be caused by their different
solubility: the thiazole derivative, being practically insoluble in water, required
a strongly alkaline pH to dissolve, whereas the guanidine derivative was easily
soluble in water.
Polar substituents modify two aspects of the behaviour of the fluorene deriva-
tives in the animal body. First, the introduction of either the free acidic groups,
-SO3H and -COOH (Argus, 1953; Argus, 1961 Malejka, 1962) or basic groups
(as in the presently described bis-guanidyl derivative, II) increase the solubility of
these compounds. This is in agreement with the general physical-chemical
phenomenon that the increase of the polar character increases the solubility of
chemical compounds because of increased hydrogen-bonding capability with water
molecules. Accordingly, -SO3NH2 groups, in which there is a relative equaliza-
tion of the electric charges, were found to confer much less solubility to the carbon
skeleton of such compounds than free acidic or basic groups (Argus, 1953 ; Argus
and Hewson, 1954; and the present results). Secondly, the free acidic groups,
-SO3H and -COOH, have been shown to confer tumour affinity to the fluorene
and biphenyl compounds, from which fact the inference has been drawn that these
compounds are bound at the cellular adsorption sites by basic proteins (Argus,
1961). The fact that the presently-described bis-guanidyl derivative does not
localize in tumour tissue gives strong support to this hypothesis.
The linking of thiazole rings to the two sulphonamido groups of fluorene-2,7-
disulphonamide appears to favour the localization in tumour tissue. The concen-
tration ofN,N'-bis(thiazole)-2,7-fluorene[35S]disulphonamide in tumour tissue was
35 ,tg. per g. tissue which, calculated for the average weight of tumour, yielded
8.03 per cent of the given dose. Autoradiograms of tumour slides showed a
considerable uptake of radioactivity by tumour cells and particularly by their
nuclei (Kasprzak, Malejka, Gabryel, 1965). The absolute value of the concentra-
tion of N,N'-bis(thiazole)-2,7-fluorene[35S]disulphonamide in tumour tissue was
higher than for the other compounds of this group previously tested (Argus,
Hudson, Seepe, Kane and Ray, 1962; Malejka, 1962). The molecular weight of
the thiazole derivative, amounting to 490.6, was the lowest; the naphthalene
derivative had 576.5 and the sulphamoyl-phenyl derivative 634. However, in
the case of the thiazole compound, the ratios of the radioactivity concentration in
tumour tissue and in the liver or spleen or kidney were lower than 0.5. These
data show once again that the presence of free acidic functional groups seems to
be necessary for achieving better selective localization of the fluorene disulphon-
amide molecule in neoplasm.
In view of the differences in localization of N,N'-bis(thiazole)-2,7-fluorene-
[35S]disulphonamide, I, between the experimental and control animals, a com-
parison of the concentration of radioactivity in blood cells, blood plasma, liver,
spleen, kidneys and urine of tumour-free Wistar rats and in the same tissues of
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tumour-bearers 6 hours after intravenous injection of compound I is given in
Table II.
TABLE II.-Comparison of the Concentration of Radioactivity in the Tissues of
Tumour-free Wistar Rats and in the Tissues of Tumour-bearing Wistar Rats
6 Hours after Intravenous Injection of N,N'-bis(thiazole)-2,7-Fluorene[35S]disul-
phonamide*
Blood
Values Blood cells plasma Liver Spleen Kidney Urine
Control group
(Tumour-free rats)
Range . . 3-23 33-211 165-905 10-110 15-100 130-850
Averaget . . . 6 114 520 59 62 619
Experimental group
(Tumour-bearing rats)
Range . . . 10-35 52-140 427-865 80-160 92-123 85-435
Averaget . . 22 80 596 120 101 276**
Ratio av. cont. 0-27 1-42 0-87 0.49 0-61 2*20 av. exp. /
Probability§ . . . 002<p<005 0 4 0 6 0 02<p<0 05 005<p<0-1 005<p<01
Meandif. ± std. dev.. . 16±6-4 34±38 76±137-7 61±23-2 39+17-8 343±169-8
* Dose of 35S-labelled compound-12 mg. per rat. Concentration in p4g. compound per ml. or g. tissue.
t Average value from 6 rats.
t Average value from 4 rats.
** Average value from 3 rats.
§ Based on null hypothesis for true difference between experimental (tumour-bearing) and control (tumour-
free) groups' values.
On examining the concentration of the disulphonamide in blood cells and
bloodplasma ofexperimental and control animals, it wasfoundthatthis compound
transferred at a slower rate from the blood cells of tumour-bearers (ratio value
0.27), while it appeared at higher concentrations in the blood plasma of tumour-
free rats (ratio value 1.42). The concentrations of radioactivity in liver were
very high but close in both groups, showing slightly enhanced uptake by the
tumour-bearers and giving a ratio of 0.87. This enhanced uptake was not,
however, statistically significant (p _ 0.60). The ratio value 0-49 calculated for
spleen showed that the organ of tumour-bearing rats localized twice as much
radioactivity as the control group. Both ratios, for blood cells and spleen, are
statistically significant (0.02 < p < 0.05). The phenomenon of greater uptake
of the radioactive compound by the liver and spleen of tumour-bearing rats than
by the same organs of controls may well be explained by the striking proliferation
of reticulo-endothelial cells which had been observed on autoradiograms of liver
and spleen in the presence ofthis tumour (Kasprzak, Malejka and Gabryel, 1965).
SUMMARY
Two new radioactive compounds: N,N'-bis(thiazole)-2,7-fluorene[35S]disul-
phonamide, I, and N,N'-bis(guanidine)-2,7-fluorene[35S]disulphonamide, II were
obtained and their tissue distribution 6 hours after a single intravenous injection
to tumour-bearing and tumour-free Wistar rats was studied. While the distri-
bution of compound I is affected by the presence of tumour, compound II is
excreted to urine in 73-80 per cent of the dose applied. The thiazole derivative
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revealed an appreciable concentration in tumour-35 ,ug. per g. tissue which was
about 8 per cent of the dose given. Blood cells, liver, spleen and kidneys of
tumour-bearing animals showed a higher concentration of radioactivity than the
same tissues of control rats. Hence, the phenomenon of impaired function
ofthe reticulo-endothelial system in the presence oftumour was not demonstrated
in this experiment. It seems, therefore, that all derivatives offluorene-2,7-disul-
phonamide may not produce consistently the same type of reaction in the
reticulo-endothelial system.
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